Business
NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors
Almonawer adds broad financial expertise to the NeOnc team WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to
About this update from Neonc Technologies Holdings, Inc.
[{"type":"text","content":"Almonawer adds broad financial expertise to the NeOnc team\nWESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, announced today that it has appointed Bader Almonawer, Managing Partner at Arabian Group, a provider of insurance solutions, to its Board of Directors. Almonawer brings significant financial and business expertise to NeOnc. \"Bader brings a wealth of capital markets and M&A experience to NeOnc,” said Dr. Thomas Chen, Chief Executive Officer of NeOnc. “His extensive finance background will serve us well as we embark on our public company journey and work toward providing enduring value to all of our stakeholders.” Almonawer is a seasoned professional with more than a decade of experience in venture capital, investment banking, and business consulting and development. Beginning his career in 2016 with McKinsey & Company and the World Bank, he later founded Oasis Capital, a VC fund that invested in numerous early-stage startups, many of which have flourished into multibillion-dollar corporations. Later, he joined Wafra Inc.'s Alternative Investments Division and gained further M&A experience at Citigroup’s M&A advisory division. “NeOnc is focused on bringing innovative medicines to diseases with high unmet needs, and I look forward to providing counsel that will help the Company achieve this goal,” said Almonawer. “With the ever-shifting dynamics of the biotech landscape, the importance of transformative treatments, such as the ones NeOnc is developing, is paramount.” “Bader’s expertise in global finance, private equity, and venture capital will be a significant asset to NeOnc as we navigate the next stage of our growth,” said Amir Heshmatpour, NeOnc’s Executive Chairman. “His strategic insights will play a crucial role in advancing our mission to bring life-changing treatments to patients battling brain cancer and other central nervous system diseases. As we expand our trials beyond the U.S., hopefully soon into the Gulf region, we believe that Bader’s regional knowledge and global perspective will be instrumental in our efforts to forge key partnerships and ensuring our therapies reach those who need them most.” Almonawer earned his Bachelor of Science in Industria...